vimarsana.com
Home
Live Updates
FDA Approves Yet Another Interchangeable Biosimilar and Anot
FDA Approves Yet Another Interchangeable Biosimilar and Anot
FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilar | McDonnell Boehnen Hulbert & Berghoff LLP
On October 3, 2023, the U.S. Food and Drug Administration (FDA) announced approval of Biogen's Byooviz (ranibizumab-nuna) as an interchangeable biosimilar to Genentech's Lucentis...
Related Keywords
Choroidal Neovascularization ,
Genentech Lucentis ,
Genentech Avastin ,
Drug Administration ,
Mcdonnell Boehnen Hulbert Berghoff ,
Mcdonnell Boehnen Hulbert ,
Age Related Macular Degeneration ,
Macular Edema Following Retinal Vein Occlusion ,
Myopic Choroidal Neovascularization ,
Bio Thera Solution ,